DataVXSmallPaper
journal article·2025-03

A Copper‐Manganese Based Nanocomposite Induces Cuproptosis and Potentiates Anti‐Tumor Immune Responses

Luoyingzi Xie, Jie Gong, Zhiqiang He, Weinan Zhang, Haoyu Wang, Shitao Wu, Xianxing Wang, Pijiang Sun, Lei Cai, Zhongjun Wu, Huaizhi Wang

Small· Volume 21· Issue 12
Publisher page
Source abstract

Abstract

Abstract Cancer is one of the most important challenges worldwide with an increasing incidence. However, most of patients with malignant cancer receiving traditional therapies have tumor recurrence and short‐term 5‐year survival. Herein, a novel Cu 2 O‐MnO@PEG (CMP) nanomaterial is developed to treat tumors. CMP directly mediates cuproptosis in tumor cells. Meanwhile, CMP potentiates anti‐tumor immune responses in the tumor microenvironment (TME) to induce tumor regression. CMP improves the tumor antigen processing and presentation of dendritic cells and tumor‐associated macrophages, and further promotes CD8 + T cell responses, especially for cytotoxic CD8 + T cells and transitory exhausted CD8 + T cells. Additionally, CMP downregulates the proportion of Treg cells and CTLA‐4 expression on Treg cells. Notably, CMP induces systemic immune responses against distant tumors and long‐term immune memory. Furthermore, CMP synergized with PD‐L1 mAb promotes tumor inhibition and sustains the anti‐tumor efficacy post PD‐L1 mAb treatment. Collectively, this strategy has the clinically therapeutic potential for tumors by facilitating cuproptosis in tumor cells and anti‐tumor immune responses.
Source: crossref · Quality: baseline

Research context

Nanomaterials

OpenAlex topics: Nanoparticle-Based Drug Delivery · Advanced Nanomaterials in Catalysis · Phagocytosis and Immune Regulation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institute of Hepatopancreatobiliary Surgery Chongqing General Hospital Chongqing University Chongqing 401147 P. R. China

Chongqing Key Laboratory of Intelligent Medicine Engineering for Hepatopancreatobiliary Diseases Chongqing 401147 P. R. China

Department of Hepatobiliary Surgery The First Affiliated Hospital of Chongqing Medical University Chongqing 400010 P. R. China

School of Clinical Medicine Chongqing Medical University Chongqing 400016 P. R. China

Department of Hepatobiliary Surgery Leshan People's Hospital Leshan 614000 P. R. China

Department of Dermatology Southwest Hospital Jiangbei Area (The 958th hospital of Chinese People's Liberation Army) Chongqing 400020 P. R. China

Department of Urinary Nephropathy Center Second Affiliated Hospital of Chongqing Medical University Chongqing 400000 P. R. China

Graduate School of Medicine Chongqing Medical University Chongqing 400016 P. R. China

Funding

National Natural Science Foundation of China · Chongqing Municipal Health Commission · Chongqing Municipal Human Resources and Social Security Bureau

References (57)

Show source-provided references
1. 10.3322/caac.2170810.3322/caac.21708 ↗
2. 10.1001/jamaoncol.2014.16110.1001/jamaoncol.2014.161 ↗
3. 10.1038/s41591-018-0014-x10.1038/s41591-018-0014-x ↗
4. 10.1001/jamadermatol.2022.016010.1001/jamadermatol.2022.0160 ↗
5. 10.1186/s12951-022-01615-210.1186/s12951-022-01615-2 ↗
6. 10.3748/wjg.v24.i43.484610.3748/wjg.v24.i43.4846 ↗
7. 10.1038/nchembio.7210.1038/nchembio.72 ↗
8. 10.1073/pnas.131843111010.1073/pnas.1318431110 ↗
9. Shanbhag V. C. · Biochim Biophys Acta Mol Cell Res. · 1868 · 2021
10. 10.1126/science.abf052910.1126/science.abf0529 ↗
11. 10.1126/science.abo395910.1126/science.abo3959 ↗
12. 10.1016/j.jconrel.2023.08.05510.1016/j.jconrel.2023.08.055 ↗
13. 10.4161/21645515.2014.98299610.4161/21645515.2014.982996 ↗
14. 10.1002/smll.20160006110.1002/smll.201600061 ↗
15. 10.1038/s41422-020-00395-410.1038/s41422-020-00395-4 ↗
16. 10.1002/adma.20220540910.1002/adma.202205409 ↗
17. 10.3390/nano1112325910.3390/nano11123259 ↗
18. 10.1016/j.it.2019.02.00310.1016/j.it.2019.02.003 ↗
19. 10.1111/cas.1231410.1111/cas.12314 ↗
20. 10.1038/s41577-019-0127-610.1038/s41577-019-0127-6 ↗
21. 10.1002/adma.20200485310.1002/adma.202004853 ↗
22. 10.1016/j.immuni.2018.11.01410.1016/j.immuni.2018.11.014 ↗
23. 10.1038/nature1933010.1038/nature19330 ↗
24. 10.1038/nature1931710.1038/nature19317 ↗
25. 10.1016/j.immuni.2018.12.02110.1016/j.immuni.2018.12.021 ↗
26. 10.1016/j.immuni.2019.11.00210.1016/j.immuni.2019.11.002 ↗
27. 10.1126/sciimmunol.abb972610.1126/sciimmunol.abb9726 ↗
28. 10.1016/j.tcb.2020.06.00310.1016/j.tcb.2020.06.003 ↗
29. 10.1038/s41577-021-00574-310.1038/s41577-021-00574-3 ↗
30. 10.1128/JVI.77.8.4911-4927.200310.1128/JVI.77.8.4911-4927.2003 ↗
31. 10.1073/pnas.080981810610.1073/pnas.0809818106 ↗
32. 10.1016/j.ccell.2018.03.01210.1016/j.ccell.2018.03.012 ↗
33. 10.1016/j.it.2017.05.00810.1016/j.it.2017.05.008 ↗
34. 10.1186/s13045-022-01322-310.1186/s13045-022-01322-3 ↗
35. 10.1056/NEJMoa120069010.1056/NEJMoa1200690 ↗
36. 10.1038/nature0444410.1038/nature04444 ↗
37. 10.1126/science.aar406010.1126/science.aar4060 ↗
38. 10.1056/NEJMoa150764310.1056/NEJMoa1507643 ↗
39. 10.1016/j.immuni.2016.04.02310.1016/j.immuni.2016.04.023 ↗
40. 10.1126/science.aae049110.1126/science.aae0491 ↗
41. 10.1126/science.aaf280710.1126/science.aaf2807 ↗
42. 10.1016/j.coi.2015.01.00610.1016/j.coi.2015.01.006 ↗
43. 10.1126/science.aaa817210.1126/science.aaa8172 ↗
44. 10.1146/annurev-med-092012-11280710.1146/annurev-med-092012-112807 ↗
45. 10.1002/adma.20200464710.1002/adma.202004647 ↗
46. 10.1021/acsnano.1c0378410.1021/acsnano.1c03784 ↗
47. 10.1186/s12951-022-01555-x10.1186/s12951-022-01555-x ↗
48. 10.1002/adfm.20240812510.1002/adfm.202408125 ↗
49. 10.1002/adma.20230803310.1002/adma.202308033 ↗
50. 10.1016/j.cej.2022.13599310.1016/j.cej.2022.135993 ↗
51. 10.1021/acsami.3c1508310.1021/acsami.3c15083 ↗
52. 10.1136/jitc-2021-00402210.1136/jitc-2021-004022 ↗
53. 10.1038/s41417-020-0183-x10.1038/s41417-020-0183-x ↗
54. 10.1158/1078-0432.CCR-21-020610.1158/1078-0432.CCR-21-0206 ↗
55. 10.1111/imr.1204110.1111/imr.12041 ↗
56. 10.3390/ijms2201007310.3390/ijms22010073 ↗
57. 10.1038/s43018-023-00521-210.1038/s43018-023-00521-2 ↗